stock price decline

Ultragenyx stock crashes 42% after disclosing failed Phase 3 trial for setrusumab; investors with losses exceeding $100,000 have until April 6, 2026 to file lead plaintiff applications in class action lawsuit.

Aldeyra Therapeutics plummets 71% after FDA rejects lead dry eye drug. Securities litigation firm investigating potential investor claims following efficacy concerns.

Coty stock plunges 15% following disappointing earnings revealing 6% revenue decline and withdrawn 2026 guidance, prompting securities fraud investigation into disclosure practices.

Robbins LLP filed class action lawsuit against $APO over concealed Jeffrey Epstein communications. Stock dropped from $133.19 to $113.73 following media exposures in February 2026.

Ultragenyx ($RARE) faces class action lawsuit over failed setrusumab Phase 3 trials, with stock down 42%. Investors have until April 6, 2026 to seek lead plaintiff status.

Immutep's $IMMP stock crashed following discontinued Phase III trial for eftilagimod alfa. Rosen Law Firm launches investigation into potential securities claims and class action lawsuit.

Weis Markets restating financials for 2022-2024 due to overstated inventory; stock drops 7.16%. Law firm investigates potential securities law violations.

Plug Power faces class action lawsuit alleging false statements about DOE loans and hydrogen facilities. Investors have until April 3, 2026 to apply as lead plaintiffs.

Ramaco Resources faces class action lawsuit over alleged false Brook Mine operational claims, with lead plaintiff deadline set for March 31, 2026.

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

Pomerantz LLP investigates Banco Santander for potential securities fraud over undisclosed UK lender collapse, with stock falling 7.57% over two trading sessions.

Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.

BlackRock faces securities fraud investigation after implementing 5% quarterly redemption caps on HPS Corporate Lending Fund, triggering 7.69% stock decline.

Pomerantz Law Firm investigates potential securities fraud at Babcock & Wilcox following allegations linking a major power contract to its largest shareholder.

Pomerantz LLP investigates Freshpet for potential securities fraud tied to unsupported 'human grade' pet food claims, triggering sharp stock decline.

Microvast ($MVST) plunged 34% after reporting $96.5M revenue (29% below consensus) and 1% gross margins, triggering securities fraud investigation by Pomerantz LLP.

Pomerantz Law Firm investigates $CFLT over undisclosed AI customer spending reduction that caused stock to crash 32.86% on July 31, 2025.

$LAKE faces class action suit alleging executives misrepresented acquisition integration and hid operational problems, leading to 39% stock crash.

Pomerantz Law Firm files class action against Enphase Energy over alleged misstatements regarding inventory management and federal solar tax credit impacts. Stock fell 15.15% after weak Q3 guidance.

Navan investors face April 2026 deadline to join class action over allegedly misleading IPO disclosures. Stock has fallen 63% after undisclosed 39% expense increase announcement.